About
On November 12, 1975, Sweden’s first allogeneic bone marrow transplantation was performed at Huddinge Hospital. Fifty years later, this pioneering achievement continues to shape the future of medicine, laying the foundation for today’s advances in cell and gene therapy.
On this special occasion, CAST – Department of Cell Therapy and Allogeneic Stem Cell Transplantation at Karolinska – invites you to a full-day scientific symposium under the theme:
“Bone Marrow Transplantation as the Basis for Modern Cell and Gene Therapy - Induced by fear of an atomic war leading to one of the greatest innovations in cancer care”
The program brings together leading experts, clinicians, and researchers from Sweden and across the globe. The day's sessions will highlight:
How to realize discovery and implementation of cell & gene therapy in Sweden
CAST’s role as a clinical and translational center
International perspectives: from bench to bedside and beyond
Clinical developments and future directions in cell and gene therapy
Keynote speakers include representatives from Karolinska Institutet, Karolinska University Hospital, the NIH (USA), and leading European institutions.
The day will conclude with reflections on past achievements and discussions on how we can continue to advance lifesaving treatments for patients worldwide.
Organizers: Professors Stephan Mielke and Mattias Carlsten, on behalf of ME CAST & USVE CAST.
Please not that the event will be documented through photos and film. If you wish not to appear in pictures or video, please contact natasha.bank@flemingsbergscience.se. Otherwise, your registration will be interpreted as consent.
Program
Arrival - Coffee and sandwiches are served
Session 1 – How to support innovation and translation of cell & gene therapy in cancer care?
10.00-10.10
“One team”: 50 years of multiprofessional experience and implementation.
Welcome to a day focusing on how innovation can reach patients!
Stephan Mielke, Professor of Hematology and Cellular Therapy;
Head of Department CAST; Program Director Allogeneic Stem Cell Transplantation and Cell Therapy
Mattias Carlsten, Associate Prof. of Hematology, Head of Research and Development CAST, Chair USVE CAST
Karolinska Institutet & University Hospital, Karolinska CCC
10.10-10.20
“One Karolinska”: From Cooperation to Integration
The vision from the two Karolinska entities to promote future developments
Christophe Pedroletti, Director Karolinska University Hospital, MD PhD
Matti Sällberg, Dean Karolinska Institutet, Professor
10.20-10.40
Keynote and motivation lecture (introduced by Prof. Stephan Mielke)
“Rapid translation of an mRNA vaccine in a moment of crisis”
About endurance and the ingredients of success!
Özlem Tureci, Professor of Personalized Immunotherapy, Helmholtz Institute for Translational Oncology (HI-TRON), Mainz, Germany
10.40-11:00
Panel discussion: Creating a culture for success!
Ugur Sahin, Professor, Scientific Chair Helmholtz Institute TRON (HI-TRON), Deputy Chairman, University Cancer Center (UCT), Mainz, Germany
Jens Hasskarl, Associate Prof. University of Freiburg, Germany, Freelancer and Strategic consultant Clinical Development, Switzerland
Samir El Andaloussi, Professor of Biomolecular Medicine and Advanced Therapy, Karolinska Institutet
Patrik Rossi, Director Theme Cancer, MD PhD, Chair of Karolinska CCC
Session 2 – The medical and research unit CAST: One clinical and translational center Chairs: Johan Törlén/Jonas Fuxe
11.00-11.15
Medical unit (ME) CAST - who are we and where are we heading?
Stephan Mielke, Professor (K/KI)
11.15-11.30
The outpatient treatment program at ME CAST – is this the future?
Sólveig Aðalsteinsdóttir, Nurse (K/KI)
11.30-11.45
Research unit (USVE) CAST – why and our mission?
Mattias Carlsten, Associate Prof. and Samir El Andaloussi,Professor (K/KI)
11.45-12.00
Questions to the speakers
LUNCH and mingle
Session 3 – International perspectives: Bringing novel cell and gene therapies to patients Chairs: Katarina LeBlanc/Yngv
13.00-13.15
The success of bench to bedside at NIH
Richard Childs, MD, National Institutes of Health (NIH), USA
Assistant U.S. Surgeon General
Scientific Director, NHLBI, NIH
Senior Investigator, Transplantation Immunotherapy, NHLBI, NIH
13.15-13.30
From BMT to CAR-T – EMBT joining forces in Europe and beyond
Ibrahim Yakoub-Agha, Professor, Lille University Hospital, France
President elect EMBT
13.30-13.45
Why clinical trial matters: How ATG changed transplant outcome
Jürgen Finke, Professor, University of Freiburg, Germany
Emeritus at Department of Hematology and Oncology
13.45-14.00
Myeloma: Early access to innovation saves lifes!
Hermann Einsele, Professor, University of Würzburg, Germany
Director of Department Medicine II
14.00-14.15
Questions to the speakers
Session 4 – Cell and gene therapies: clinical developments and research for the future Jacek Toporski/Piotr Kozlowski
14.15-14.30
Mesenchymal stromal cells: From development to implementation
Katarina LeBlanc, Professor (K/KI)
14.30-14.45
Treatments of immunodeficiencies/Gene therapy in the pediatric population
Mikael Sundin, Associate Prof. (K/KI)
14.45-15.10
5-minute presentations from PhD students of Research unit (USVE) CAST
Gene therapy for sickle cell anemia
Maria Morello-Miravet (Mielke group)
Reprogramming NK cells for the treatment of AML
Caroline Eriksson (Carlsten group)
Neuroinflammation a mystery in allogeneic SCT and CAR-T
Ksenia Boriskina (Mielke/LeBlanc groups)
Engineered exosomes for CNS gene editing
Houze Zhou (El Andaloussi group)
A Novel Prophylactic Strategy Against the Acute Graft-versus-Host Disease Yikai Yin (Zhao/Hassan groups)
Session 5 – Conclusions and mingle
15.25-15.30 Concluding remarks
Prof. Stephan Mielke and Associate Prof. Mattias Carlsten (K/KI)
15:30 -16:30 Mingle & music
Sponsors
Bristol Mayers Squibb
Medac
Scandinavian Biopharma
Gilead Sciences
Cancerfonden
Supported by
